A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
By D. Fergusson, Paul C. Hébert, C. Mazer, S. Fremes, C. MacAdams, J. Murkin, K. Teoh, P. Duke, R. Arellano, M. Blajchman and 9 more. New England Journal of Medicine, 2008
1,109 citations recorded by the source corpus.
Subfields: Biochemistry, Hematology, Surgery
View Paper: https://www.semanticscholar.org/paper/15dbafa5951067dad4097ead894515280e923a6f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Surgery
Citations in the corpus
- The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition (2019, background): “Due to concerns about safety [510], the use of aprotinin is not advised in bleeding trauma patients,”
- Management of bleeding following major trauma: an updated European guideline (2010, background): “Since the last guidelines were written, aprotinin has been associated with patient safety issues, with an increased rate of renal disease and mortality when compared with the lysine analogues in a large clinical trial and is therefore no longer recommended [293-296].”
- 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. (2011, background): “The wide-spread adoption of antifibrinolytic therapies for cardiac surgery stimulated concern over the safety and efficacy of these drugs [38, 63–69].”
- The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition (2016, background): “Due to concerns about safety [419] the use of aprotinin is not advised in bleeding trauma patients, now that TXA has been shown to be efficacious and safe.”